These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 24676243

  • 1. [In vitro emergence of ertapenem resistance in Escherichia coli producing extended-spectrum β-lactamase].
    Villar HE, Jugo MB, Visser M, Hidalgo M, Hidalgo G, Maccallini GC.
    Rev Esp Quimioter; 2014 Mar; 27(1):51-5. PubMed ID: 24676243
    [Abstract] [Full Text] [Related]

  • 2. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
    Kuzucu C, Yetkin F, Görgeç S, Ersoy Y.
    Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
    [Abstract] [Full Text] [Related]

  • 3. Carbapenem MICs in Escherichia coli and Klebsiella Species Producing Extended-Spectrum β-Lactamases in Critical Care Patients from 2001 to 2009.
    Johnson JK, Robinson GL, Pineles LL, Ajao AO, Zhao L, Albrecht JS, Harris AD, Thom KA, Furuno JP.
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167543
    [Abstract] [Full Text] [Related]

  • 4. Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms.
    Mody RM, Erwin DP, Summers AM, Carrero HA, Selby EB, Ewell AJ, Moran KA.
    Ann Clin Microbiol Antimicrob; 2007 Jun 06; 6():6. PubMed ID: 17553151
    [Abstract] [Full Text] [Related]

  • 5. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR, Frei CR, Burgess DS.
    Clin Ther; 2004 Nov 06; 26(11):1800-7. PubMed ID: 15639692
    [Abstract] [Full Text] [Related]

  • 6. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
    DeRyke CA, Banevicius MA, Fan HW, Nicolau DP.
    Antimicrob Agents Chemother; 2007 Apr 06; 51(4):1481-6. PubMed ID: 17283197
    [Abstract] [Full Text] [Related]

  • 7. In vitro activity of ertapenem and other carbapenems against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae clinical isolates in a tertiary care center in Turkey.
    Kiremitci A, Dinleyici EC, Erben N, Durmaz G, Yargic ZA, Aybey AD, Usluer G.
    Expert Opin Pharmacother; 2008 Jun 06; 9(9):1441-9. PubMed ID: 18518776
    [Abstract] [Full Text] [Related]

  • 8. Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009).
    Hawser SP, Bouchillon SK, Lascols C, Hackel M, Hoban DJ, Badal RE, Cantón R.
    Clin Microbiol Infect; 2012 Mar 06; 18(3):253-9. PubMed ID: 21635662
    [Abstract] [Full Text] [Related]

  • 9. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
    Raveh D, Yinnon AM, Broide E, Rudensky B.
    Chemotherapy; 2007 Mar 06; 53(3):185-9. PubMed ID: 17347564
    [Abstract] [Full Text] [Related]

  • 10. [Investigation of carbapenemases in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains isolated in 2014 in Turkey].
    Çakar A, Akyön Y, Gür D, Karatuna O, Öğünç D, Özhak Baysan B, Çöplü N, Çağatay M, Kılıç A, Baysallar M, Bakıcı Z, Çelik C, Gülay Z, Aydemir Ş, Tünger A, Kılıç H, Erçal BD, Aşçı Toraman Z, Zer Y, Büyüktaş A, Ay S, Aktaş Z, Kayacan Ç, Bayramoğlu G, Aydın F, Dündar D, Hasdemir U, Ayaş R, Yanık K, Günaydın M, Güdücüoğlu H, Parlak M.
    Mikrobiyol Bul; 2016 Jan 06; 50(1):21-33. PubMed ID: 27058326
    [Abstract] [Full Text] [Related]

  • 11. Nosocomial blood-stream infections from extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumonia from GB Pant Hospital, New Delhi.
    Taneja J, Mishra B, Thakur A, Dogra V, Loomba P.
    J Infect Dev Ctries; 2010 Sep 03; 4(8):517-20. PubMed ID: 20818104
    [Abstract] [Full Text] [Related]

  • 12. Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model.
    Tängdén T, Adler M, Cars O, Sandegren L, Löwdin E.
    J Antimicrob Chemother; 2013 Jun 03; 68(6):1319-26. PubMed ID: 23478794
    [Abstract] [Full Text] [Related]

  • 13. Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009.
    Jean SS, Lee WS, Bai KJ, Yu KW, Hsu CW, Yu KW, Liao CH, Chang FY, Ko WC, Wu JJ, Chen YH, Chen YS, Liu JW, Lu MC, Liu CY, Chen RJ, Hsueh PR.
    Diagn Microbiol Infect Dis; 2015 Apr 03; 81(4):290-5. PubMed ID: 25600841
    [Abstract] [Full Text] [Related]

  • 14. Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain.
    Hernández JR, Velasco C, Romero L, Martínez-Martínez L, Pascual A.
    Int J Antimicrob Agents; 2006 Nov 03; 28(5):457-9. PubMed ID: 17008066
    [Abstract] [Full Text] [Related]

  • 15. Faropenem resistance causes in vitro cross-resistance to carbapenems in ESBL-producing Escherichia coli.
    Gandra S, Choi J, McElvania E, Green SJ, Harazin M, Thomson RB, Dantas G, Singh KS, Das S.
    Int J Antimicrob Agents; 2020 Mar 03; 55(3):105902. PubMed ID: 31954833
    [Abstract] [Full Text] [Related]

  • 16. Ertapenem susceptibility of extended spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care centre in India.
    Behera B, Mathur P, Das A, Kapil A.
    Singapore Med J; 2009 Jun 03; 50(6):628-32. PubMed ID: 19551319
    [Abstract] [Full Text] [Related]

  • 17. Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil.
    Kiffer CR, Kuti JL, Eagye KJ, Mendes C, Nicolau DP.
    Int J Antimicrob Agents; 2006 Oct 03; 28(4):340-4. PubMed ID: 16930951
    [Abstract] [Full Text] [Related]

  • 18. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
    Zhanel GG, Pozdirca M, Golden AR, Lawrence CK, Zelenitsky S, Berry L, Schweizer F, Bay D, Adam H, Zhanel MA, Lagacé-Wiens P, Walkty A, Irfan N, Naber K, Lynch JP, Karlowsky JA.
    Drugs; 2022 Apr 03; 82(5):533-557. PubMed ID: 35294769
    [Abstract] [Full Text] [Related]

  • 19. Low frequency of ertapenem-resistant intra-abdominal isolates of Escherichia coli from Latin America: susceptibility, ESBL-occurrence, and molecular characterisation (SMART 2008-2009).
    Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Hackel MA, Lascols CA, Villegas MV, Rossi F.
    J Chemother; 2012 Feb 03; 24(1):6-11. PubMed ID: 22546718
    [Abstract] [Full Text] [Related]

  • 20. Comparison of in vitro efficacy of ertapenem, imipenem and meropenem in the infections caused by the Enterobacteriaceae strains family.
    Guzek A, Tomaszewski D, Rybicki Z, Truszczyński A, Barański M, Korzeniewski K.
    Anaesthesiol Intensive Ther; 2013 Feb 03; 45(2):67-72. PubMed ID: 23877897
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.